Recordati, IT0003828271

Recordati S.p.A. Stock (IT0003828271): OPA filing keeps delisting bid in focus

12.06.2026 - 20:36:52 | ad-hoc-news.de

Recordati is in focus after Respighi BidCo filed its offer document with Consob for a voluntary all-cash takeover at 51.29 euros per share, a step tied to a possible delisting from Piazza Affari.

Recordati, IT0003828271
Recordati, IT0003828271

Responsible: ad hoc news Stocks & Analysis Desk. Reviewed prior to publication on June 12, 2026 at 6:36 PM ET. Details in the imprint.

Recordati shares are in focus after Respighi BidCo filed its offer document with Consob on June 11, 2026, moving the planned voluntary tender offer one step closer to formal review. The bid values Recordati at 51.29 euros per share in cash and implies a total transaction value of about 10.7 billion euros, according to company-related reports and Borsa Italiana coverage.

What the filing changes

The document filing is a procedural milestone, not a closing event. Consob still has to review the prospectus before publication, and the offer remains subject to regulatory clearances including antitrust and foreign investment-related approvals, as described in the published reports.

The transaction is designed as a full takeover of all outstanding ordinary shares, with delisting from Piazza Affari as a stated objective. That makes the current market focus less about operating performance and more about the legal path from filing to approval to acceptance period.

On Borsa Italiana, Recordati ordinary shares last traded at 50.90 euros, with the intraday range shown at 50.90 to 51.15 euros and the open at 51.10 euros. That puts the stock very close to the 51.29-euro offer price, which helps explain why the latest move was reported as flat at 0.00%.

For US investors, the key takeaway is that the share price is now anchored by a cash bid rather than by a standalone earnings or valuation debate. Recordati is listed in Milan, not on the NYSE or Nasdaq, so the relevant reference point today is the Italian listing and the terms of the proposed offer.

The latest reports also indicate that no competing bid has been disclosed so far, leaving Respighi BidCo as the sole named buyer in the public record. If that remains the case, the market will continue to trade mainly on approval timing, offer documentation and the probability that the transaction proceeds on the announced terms.

Against this backdrop, Recordati remains a stock in transition rather than a normal fundamental story. The next catalyst is the regulator's review, and until that process advances, the shares are likely to stay tightly linked to the takeover price and the latest procedural headlines.

Recordati stock at a glance

  • Name: Recordati S.p.A.
  • Industry: Pharmaceuticals
  • Headquarters: Milan, Italy
  • Core markets: Europe and other international pharmaceutical markets
  • Revenue drivers: Prescription medicines, specialty treatments and international sales
  • Listing: Borsa Italiana, FTSE MIB constituent; no NYSE or Nasdaq listing verified in the provided sources
  • Trading currency: Euro

More Recordati news at a glance

Track the latest takeover filings, market reaction and any new regulatory steps affecting the shares.

More Recordati S.p.A. newsInvestor Relations

What traders are watching on Recordati

YouTubeXTikTokInstagram

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.

en | IT0003828271 | RECORDATI | boerse | 69529752 | bgmi